185 related articles for article (PubMed ID: 22639162)
1. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma.
Ursu R; Carpentier AF
Adv Exp Med Biol; 2012; 746():95-108. PubMed ID: 22639162
[TBL] [Abstract][Full Text] [Related]
2. CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma.
Carpentier AF; Auf G; Delattre JY
Front Biosci; 2003 Jan; 8():e115-27. PubMed ID: 12456326
[TBL] [Abstract][Full Text] [Related]
3. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
Auf G; Carpentier AF; Chen L; Le Clanche C; Delattre JY
Clin Cancer Res; 2001 Nov; 7(11):3540-3. PubMed ID: 11705874
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of oligodeoxynucleotides containing synthetic immunostimulatory motifs in weaned piglets.
Zhang L; Tian X; Zhou F
Int Immunopharmacol; 2006 Oct; 6(10):1623-31. PubMed ID: 16919835
[TBL] [Abstract][Full Text] [Related]
6. CpG-ODN increases resistance of olive flounder (Paralichthys olivaceus) against Philasterides dicentrarchi (Ciliophora: Scuticociliatia) infection.
Lee EH; Kim KH
Fish Shellfish Immunol; 2009 Jan; 26(1):29-32. PubMed ID: 18992348
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs.
Carpentier AF; Xie J; Mokhtari K; Delattre JY
Clin Cancer Res; 2000 Jun; 6(6):2469-73. PubMed ID: 10873101
[TBL] [Abstract][Full Text] [Related]
8. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response.
Weighardt H; Feterowski C; Veit M; Rump M; Wagner H; Holzmann B
J Immunol; 2000 Oct; 165(8):4537-43. PubMed ID: 11035094
[TBL] [Abstract][Full Text] [Related]
9. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
Alizadeh D; Zhang L; Brown CE; Farrukh O; Jensen MC; Badie B
Clin Cancer Res; 2010 Jul; 16(13):3399-408. PubMed ID: 20570924
[TBL] [Abstract][Full Text] [Related]
10. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
[TBL] [Abstract][Full Text] [Related]
11. Hierarchical recognition of CpG motifs expressed by immunostimulatory oligodeoxynucleotides.
Klinman DM; Currie D
Clin Exp Immunol; 2003 Aug; 133(2):227-32. PubMed ID: 12869028
[TBL] [Abstract][Full Text] [Related]
12. TLR ligands in the local treatment of established intracerebral murine gliomas.
Grauer OM; Molling JW; Bennink E; Toonen LW; Sutmuller RP; Nierkens S; Adema GJ
J Immunol; 2008 Nov; 181(10):6720-9. PubMed ID: 18981089
[TBL] [Abstract][Full Text] [Related]
13. Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer.
Jahrsdörfer B; Weiner GJ
Semin Oncol; 2003 Aug; 30(4):476-82. PubMed ID: 12939716
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
Ishii KJ; Gursel I; Gursel M; Klinman DM
Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
[TBL] [Abstract][Full Text] [Related]
15. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection.
Verthelyi D; Gursel M; Kenney RT; Lifson JD; Liu S; Mican J; Klinman DM
J Immunol; 2003 May; 170(9):4717-23. PubMed ID: 12707351
[TBL] [Abstract][Full Text] [Related]
16. Use of CpG oligodeoxynucleotides as immunoprotective agents.
Klinman DM
Expert Opin Biol Ther; 2004 Jun; 4(6):937-46. PubMed ID: 15174975
[TBL] [Abstract][Full Text] [Related]
17. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
Jahrsdörfer B; Weiner GJ
Curr Opin Investig Drugs; 2003 Jun; 4(6):686-90. PubMed ID: 12901226
[TBL] [Abstract][Full Text] [Related]
18. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
Weiner GJ
J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
[TBL] [Abstract][Full Text] [Related]
19. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
20. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
Klinman DM; Klaschik S; Sato T; Tross D
Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
